VIR — Vir Biotechnology Income Statement
0.000.00%
Last trade - 00:00
- $1.07bn
- -$448.90m
- $86.18m
- 56
- 26
- 17
- 24
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8.09 | 76.4 | 1,095 | 1,616 | 86.2 |
Cost of Revenue | |||||
Gross Profit | — | — | 1,030 | 1,469 | 83.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 186 | 373 | 675 | 783 | 770 |
Operating Profit | -178 | -297 | 421 | 833 | -684 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -175 | -299 | 550 | 754 | -628 |
Provision for Income Taxes | |||||
Net Income After Taxes | -175 | -299 | 529 | 516 | -615 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -175 | -299 | 529 | 516 | -615 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -175 | -299 | 529 | 516 | -615 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.76 | -2.51 | 3.96 | 3.83 | -4.59 |